A Multicenter, Randomized, Double-Blind, Placebo-Controlled, 12-Month Study to Evaluate the Efficacy and Safety of Oral Alendronate Sodium Once Weekly for the Prevention and Treatment of Glucocorticoid-Induced Bone Loss

NCT00480766 Phase 3 COMPLETED

A research study to see how safe and effective MK0217 is when taken weekly for the prevention and treatment of steroid induced bone loss.

Details

Lead sponsor	Organon and Co
Phase	Phase 3
Status	COMPLETED
Enrolment	173
Start date	2001-07
Completion	2003-08

Conditions

• Osteoporosis

Interventions

• MK0217/Duration of Treatment : 12 Months

Primary outcomes

• Assess the effect of patients taking MK0217 once weekly along with steroids for a 12 month period by checking the percentage change of bone mineral density as compared to patients taking placebo